Working… Menu

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03576131
Recruitment Status : Recruiting
First Posted : July 3, 2018
Last Update Posted : July 14, 2021
Information provided by (Responsible Party):

Brief Summary:
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors

Condition or disease Intervention/treatment Phase
Colorectal Cancer Non-small Cell Lung Cancer Triple Negative Breast Cancer Renal Cell Carcinoma Gastric Cancer Pancreatic Cancer Urothelial Cancer Biological: GEN1029 (HexaBody®-DR5/DR5) Phase 1 Phase 2

Detailed Description:
The trial is an open-label, multi-center safety trial of GEN1029 (HexaBody®-DR5/DR5). The trial consists of two parts a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 520 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Actual Study Start Date : May 7, 2018
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: GEN1029 (HexaBody®-DR5/DR5)
Open label, single arm trial where GEN1029 will be administered
Biological: GEN1029 (HexaBody®-DR5/DR5)
GEN1029 will be administered intravenously once every 14 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.

Primary Outcome Measures :
  1. Dose Limiting Toxicities (DLTs) [ Time Frame: DLTs will be identified from the two first treatment cycles (28 days, a cycle is 14 days) ]
    To determine recommended phase 2a dose of GEN1029

  2. Adverse events (AEs) [ Time Frame: Throughout and at the end of trial (up to 24 months after first treatment cycle (a treatment cycle is 14 days)) ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria (main):

  • Patients with advanced and/or metastatic cancer who have no available standard therapy or who are not candidates for available standard therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1029 may be beneficial.
  • Patient must be ≥ 18 years of age
  • Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
  • Have an acceptable hematological status
  • Have an acceptable renal function
  • Have an acceptable liver function
  • Have an Eastern Cooperative Oncology Group performance status of 0 or 1
  • Body weight ≥ 40kg
  • Patients both females and males, of childbearing or reproductive potential must agree to use adequate contraception from screening visit until six months after last infusion of GEN1029

Exclusion Criteria (main):

  • Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 8 weeks prior to first GEN1029 administration
  • Have clinically significant cardiac disease
  • Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive brain metastases or stroke
  • History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of Investigational Medicinal Product (IMP)
  • Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first GEN1029 administration
  • History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial
  • Radiotherapy within 14 days prior to first GEN1029 administration
  • Any prior therapy with a compound targeting DR4 or DR5
  • History of chronic liver disease or evidence of hepatic cirrhosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03576131

Layout table for location contacts
Contact: Genmab Trial Information +45 70202728

Layout table for location information
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06510
United States, Texas
UT M.D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Hospital Univeritario Vall d'Hebron Recruiting
Barcelona, Spain
START Madrid CIOCC Recruiting
Madrid, Spain
United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust Recruiting
Newcastle, United Kingdom
The Royal Mardsen NHS Foundation Trust Recruiting
Sutton, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Ruth Plummer, Professor Newcastle Hospitals NHS Foundation Trust
Layout table for additonal information
Responsible Party: Genmab Identifier: NCT03576131    
Other Study ID Numbers: GCT1029-01
First Posted: July 3, 2018    Key Record Dates
Last Update Posted: July 14, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Breast Neoplasms
Breast Diseases
Skin Diseases